MAZE · Maze Therapeutics

The thesis

Maze Therapeutics' kidney drug MZE829 has an early efficacy signal and cash guided into 2029, but the shares are more likely to lag the S&P 500 over the next three months. The company's Q3 2026 report, filed on 9 November 2026, moved full Phase 2 HORIZON data to early 2027, and the shares rose into that longer wait. The all-cohort HORIZON readout settles the call.

The shares closed at $36.73 on 11 November 2026, up from $32.53 on 5 November 2026. The price context puts the three-month gain at 32.8%. A third-party summary of the 9 November 2026 results (finsee.ai) says the late-2026 data window was dropped and the data are now expected in early 2027. The company reported a Q3 loss of $0.79 per share against a $0.77 loss estimate, according to company news on 9 November 2026.

Analysts updated targets after the report. JP Morgan kept Overweight and lowered its target to $51 on 11 November 2026. Wedbush kept Outperform and raised its target to $49 on 10 November 2026.

Bullish and bearish views on Maze Therapeutics, Inc.

The bull case on Maze Therapeutics, Inc. (MAZE), in brief: an early kidney signal exists. The bear case: the data date moved later.

Bull case

• An early kidney signal exists. Maze's 25 March 2026 HORIZON topline reported a mean 35.6% reduction in urine albumin-to-creatinine ratio, a measure of protein leaking into urine, at week 12 in broad APOL1-mediated kidney disease. Patients with focal segmental glomerulosclerosis (FSGS) showed a 61.8% mean reduction and non-diabetic patients 48.6%.
• Funding runs past the next readouts. Maze held $477.0 million in cash and marketable securities at 30 September 2026, and the company still guides to funding operations into 2029, according to the finsee.ai summary of the 9 November 2026 results.
• A pivotal start is still planned for the first half of 2027. The same summary says the MZE829 pivotal trial start is subject to regulatory feedback, and enrollment in HORIZON is complete.
• Sell-side targets sit well above the price. JP Morgan's target is $51 (11 November 2026) and Wedbush's is $49 (10 November 2026), both with positive ratings and both set after the Q3 report.

Bear case

• The data date moved later. The finsee.ai summary of the Q3 report says full HORIZON results are now expected in early 2027, where management had guided to late 2026 or early 2027 on 15 September 2026. Maze also pushed the start of a Phase 2 trial of MZE782 in chronic kidney disease to the first half of 2027 from the second half of 2026.
• Efficacy rests on a small sample. The March topline included 15 patients in the safety analysis and 12 evaluable for efficacy. Management said on 15 September 2026 that the remaining cohorts of 10–15 patients each include patients already disclosed.
• The shares have rallied without new clinical data. The close rose from $32.53 on 5 November 2026 to $36.73 on 11 November 2026, a period in which the report moved the data date later. Maze described its 24 October 2026 Kidney Week talk as previously reported data with added detail.
• Spending keeps rising. Research and development expense was $40.2 million in Q3 2026 (finsee.ai summary), against $34.9 million in the quarter ended 30 June 2026 (Form 10-Q).
• Insiders sell on schedule. Chief Executive Officer Jason Coloma sold 34,501 shares at an average $30.25 on 2 November 2026, under a Rule 10b5-1 pre-arranged plan, according to a Form 4 filed 4 November 2026. Atul Dandekar sold 7,500 shares at $32.07 on 29 October 2026 under a similar plan.
• Maze has financed after data before. The April 2026 placement priced at $23.50 per share.

Price setup

The close of $36.73 on 11 November 2026 is above the 50-day average of $28.33 and the 200-day average of $31.46, both from adjusted daily closes. The shares have climbed through six sessions in a row from the $33.38 close on 4 November 2026, with the 5 November 2026 close of $32.53 the one lower close along the way.

The 52-week closing low is $22.39, set on 21 September 2026. The 52-week high is $53.65 (intraday, 16 March 2026), and the last close is 31.5% below it.

Maze's cash runway and the pivotal start timetable are unchanged on the company's account. The open item is the early-2027 HORIZON data, which can land inside or just beyond the three-month window that ends in early February 2027.

Catalysts ahead

• 30 November 2026 (est.): Investor conference presentations announced by Maze on 3 November 2026 (dates not confirmed). Management commentary can restate or change the HORIZON data date and the pivotal timetable.
• early 2027 (company guidance): HORIZON Phase 2 data across all three cohorts. Shows whether the proteinuria reduction holds in non-diabetic, diabetic and severe FSGS patients, and supports the pivotal design.
• first half of 2027 (company guidance): Planned start of the MZE829 pivotal trial and of the MZE782 Phase 2 trial in chronic kidney disease. Confirms regulatory feedback and shows whether the timetable slips further.
• early 2027 (per Canaccord): Vertex inaxaplin Phase 2/3 topline data. The class comparator's result cross-reads to MZE829 and could set the APOL1 bar before Maze starts a pivotal trial.

What would change the view

A daily close above $41.50, well over the 11 November 2026 close of $36.73, which would show the shares leading the S&P 500 despite the later data date. HORIZON data across all three cohorts that hold the proteinuria reduction would also show the shares leading.

What it trades with

MAZE trades on its own clinical news more than on sector moves. Vertex's inaxaplin, the other APOL1 kidney drug in late-stage testing, is the main cross-read in both directions. Canaccord Genuity said on 19 October 2026 that it expects Vertex's Phase 2/3 topline data in early 2027. Small-cap biotech funding conditions affect the odds and price of any new Maze equity raise.